Cryo-Save Group N.V. – Board change

June 25, 2013 Group News

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces today that Mr Johan Goossens decided to step back from office as a Non-Executive Board Member with immediate effect.

read more

Board change

May 23, 2013 Group News

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Company’), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces that the Board of Directors has decided to appoint its Non-Executive Director Mr. Walter van Pottelberge as Chairman of the Board as of today. Mr. Van Pottelberge will replace Mr. Johan Goossens, who will remain a NonExecutive Director.

Director shareholding – Block-trades

May 10, 2013 Group News

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, has been informed that via a block-trade Mr Johan Goossens, Chairman, sold 900,000 ordinary shares of Euro 0.10 (‘Ordinary Shares’) to Salveo Holding SA on 7 May 2013 and that at the same day Mr Marc Waeterschoot, co-founder and former Board Member of Cryo-Save, via a block-trade sold 1,460,000 Ordinary Shares to Salveo Holding SA, both at a price of €1.70. Salveo Holding SA has not contacted management of Cryo-Save about its intentions as a major shareholder.

read more

Cryo-Save Group N.V. – Board change

November 26, 2012 Group News

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international family stem cell bank and the largest bank in Europe, announces that Marc Waeterschoot has stepped down as Non-Executive Director for personal reasons. Mr. Waeterschoot, co-founder of the Company, has been actively involved in Cryo-Save for over 12 years and will remain a shareholder in the Company.

read more

Director Shareholding

June 30, 2011 Group News

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international family stem cell bank, has been informed that Mr Johan Goossens, Chairman, purchased 10,000 ordinary shares of Euro 0.10 (‘Ordinary Shares’) at a price of €4.92 on 29 June 2011.

read more

Director Shareholding

June 24, 2011 Group News

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international family stem cell bank, has been informed that Mr Johan Goossens, Chairman, purchased 10,000 ordinary shares of Euro 0.10 (‘Ordinary Shares’) at a price of €4.95 on 23 June 2011.

read more

EN – Director/PDMR Shareholding

July 27, 2010 Group News

Cryo-Save Group N.V.(Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), Europe’s leading stem cell bank, has been informed today that Mr Johan Goossens, Chairman, purchased 16,000 ordinary shares of Euro 0.10 (‘Ordinary Shares’) at €5.78 on 26 July 2010.

Following this purchase, Johan Goossens is beneficially interested in 1,671,000 ordinary shares, representing approximately 18.08% of the Company’s issued share capital.

read more

NL – Director/PDMR Shareholding

July 27, 2010 Group News

Aankoop aandelen Chairman

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, of ‘de Groep’), de grootste stamcelbank van Europa, is vandaag geïnformeerd dat de heer Johan Goossens, Chairman, 16.000 aandelen Cryo-Save heeft gekocht tegen €5,78 op 26 juli 2010.

Het aandelenbelang in de Groep van de heer Goossens na deze transactie bedraagt 1.671.000 aandelen, ofwel 18,08% van het geplaatst aandelenkapitaal van de Groep.

read more

EN – Director/PDMR Shareholding

May 17, 2010 Group News

Cryo-Save Group N.V.(AIM/Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), Europe’s leading stem cell bank, has been informed today that Mr Johan Goossens, Chairman, purchased 25,000 ordinary shares of Euro 0.10 (‘Ordinary Shares’) at €5.78 on 14 May 2010.

Following this purchase, Johan Goossens is beneficially interested in 1,655,000 ordinary shares, representing approximately 17.92% of the Company’s issued share capital.

read more

Page 1 of 3123